CORE--CLINICAL LABORATORY CORE

行政和临床化学核心的目的是为项目提供全面的日常行政指导，并为本计划项目资助伞下提出的无数生化分析提供实验室支持。通过在核心实验室环境中进行这些测定，我们将实现本提案所需的用品和实验室人员的成本效益利用。更重要的是，它将确保对这些分析的性能进行质量控制，并最大限度地减少执行各自测试方案的几个实验室之间可能发生的潜在差异。所有尿液分析将在CLIA批准的矿物质代谢实验室进行。程序都是标准化的，并包括适当的质量控制标本 每次跑步。在本实验室进行的分析将有助于每个组件， 表A中规定。组分I、II、IV和V将需要24小时尿液分析以确定结石风险 参数还将对2小时空腹标本进行类似检测，作为 第一和第二部分。可滴定酸度将是组分II的主要需求，而组分II的次要需求是可滴定酸度。 构成部分四.血清测定将需要使用ELISA和放射性同位素方法。这些试验将在Dr. Zerwekh的指导下在RIA实验室进行。除维生素D代谢物分析外，所有拟定检测均采用市售试剂盒进行，目前在本实验室采用。组分III将需要对大鼠尿液和血浆进行有限的电解质评估。将在组分II的共同研究者Dr. Nicola Abate的实验室中进行组分II特异性的三项测定，即血清胰岛素、游离脂肪酸和乳酸盐。

The purpose of the administrative and clinical chemistry core is to provide overall daily administrative guidance for the project and laboratory support for the myriad of biochemical analyses proposed under the umbrella of this program project grant. By performing these determinations in a core laboratory setting, we will attain cost-effective utilization of the supplies and laboratory personnel required for this proposal. More importantly, it will insure quality control over the performance of these analyses and minimize the potential variation that might occur between several laboratories performing their own testing protocols. All of the urinary analyses will be performed in the Mineral Metabolism laboratory, a CLIA-approved laboratory. The procedures are all standardized and appropriate quality control specimens are included with each run. The analyses to be performed in this laboratory will subserve each component as specified in Table A. Components I, II, IV, and V will require 24-hour urine analyses for stone-risk parameters. Similar testing will also be accomplished on 2-hour fasting specimens as part of Components I and II. Titratable acidities will be a major need for component II and a minor part of component IV. Serum assays will require the use of both ELISA and radioisotopic methods. These assays will be performed in the RIA laboratory under the direction of Dr. Zerwekh. Except for the vitamin D metabolite analyses, all of the proposed tests are performed with commercially available kits and are currently employed assays in this laboratory. Component III will require a limited electrolyte assessment on rat urine and plasma. Three of the assays specific to component II, namely serum insulin, free fatty acid, and lactate will be performed in the laboratory of Dr. Nicola Abate, co-investigator for Component II.